NeuroSense

Home>Tag:NeuroSense
Oct 27 2025

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

By |2025-10-25T17:19:11-04:00October 27th, 2025|Featured, Investor News, Press Releases, Technology|0 Comments

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Jackson Center, PA – October 27, 2025 – Halberd Corporation (OTC: HALB) today announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, ...

Read More
Sep 29 2025

Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment

By |2025-09-28T20:11:12-04:00September 29th, 2025|Investor News, News, Press Releases|0 Comments

First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA – September 29, 2025 – Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain ...

Read More
INVESTOR/MEDIA INQUIRIES

MEDICAL METAVERSE

As part of our efforts to remain at the forefront of breakthrough technologies in the medical and scientific fields, Halberd Corporation is engaged in scientific study and research in the fields of medicine, the prevention, treatment and management of illness and infections and rapid tests to identify infection, and other medical maladies.

To learn more about how we can further your efforts, or to partner with Halberd on specific healthcare solutions, please email: info@halberdcorporation.com

Go to Top